| Literature DB >> 16886901 |
Federico Goodsaid1, Felix Frueh.
Abstract
How can we encourage the application of novel genomic biomarkers in drug development? A major step in this direction would be a consensus on how to interpret results from measurements of these biomarkers in regulatory submissions. A transparent process for genomic biomarker validation would be of value both for the pharmaceutical industry as well as for regulatory agencies associated with it. A discussion on process map proposals for genomic biomarker validation can help with drafting of guidance documents for this process.Mesh:
Substances:
Year: 2006 PMID: 16886901 DOI: 10.2217/14622416.7.5.773
Source DB: PubMed Journal: Pharmacogenomics ISSN: 1462-2416 Impact factor: 2.533